H-001
氢氯噻嗪 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
产品名称
氢氯噻嗪 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
InChI key
JZUFKLXOESDKRF-UHFFFAOYSA-N
InChI
1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
SMILES string
NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Quality Level
Gene Information
human ... SLC12A3(6559)
General description
氢氯噻嗪是一种保钙利尿剂，用于水肿和高血压的治疗。噻嗪类衍生物，氢氯噻嗪以商品名Microzide®和Aquazide H出售。该认证的加标溶液®适用于LC/MS或GC/MS应用，例如临床毒理学和法医分析。
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Microzide is a registered trademark of Watson Laboratories, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Yoshihisa Hanayama et al.
Acta medica Okayama, 66(6), 449-459 (2012-12-21)
Angiotensin receptor blockers (ARBs) are the first-line antihypertensive agents. In clinical practice, it is often difficult to achieve the recommended blood pressure level by ARBs in their ordinal dosages alone. This study examined the practical efficacy of a combination therapy
Alexander V Murray et al.
Journal of clinical hypertension (Greenwich, Conn.), 14(12), 821-827 (2012-12-05)
Combination antihypertensive therapies are recommended to attain blood pressure (BP) targets especially in high-risk patients in whom rapid and pronounced BP control is essential. This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination
Michael A Weber et al.
Lancet (London, England), 381(9866), 537-545 (2012-12-12)
In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal weight compared with obese individuals. As a prespecified analysis of the Avoiding Cardiovascular Events through Combination Therapy in Patients Living
Successful rapid desensitization to hydrochlorothiazide.
Jamma Li et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 110(4), 307-308 (2013-03-29)
Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Brent Egan et al.
Journal of hypertension, 31(2), 259-260 (2013-01-11)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持